No profile photo available

Joanne LaFleur, PharmD, MSPH

Languages spoken: English

Academic Information

Departments Primary - Pharmacotherapy

Education History

Undergraduate University of Utah
 BS
Doctoral Training University of Utah
 PharmD
Graduate Training University of Utah
 MS
Fellowship University of Utah, Pharmacotherapy Outcomes Research Center
 Fellow

Selected Publications

Journal Article

  1. LaFleur J, Hoop R, Korner E, DuVall S, Morgan T, Pandya P, Knippenberg K, Nelson R (2013). Predictors of early discontinuation of pegylated interferon for reasons other than lack of efficacy in United States veterans with chronic hepatitis C. Gastroenterology nursing,
  2. Nelson RE, Nebeker JR, Sauer BC, LaFleur (2012). Factors associated with screening or treatment initiation among male United States veterans at risk for osteoporosis fracture. Bone, 50(4), 983-8. (Read full article)
  3. Lafleur J, DuVall SL, Willson T, Ginter T, Patterson O, Cheng Y, Knippenberg K, Hayden C, Alder RA, Curtis JR, Agodoa I, Nelson R Analysis of osteoprosis treatment patterns and outcomes among postmenopausal veterans. Bone,
  4. Nelson RE, Hoop R, Korner E, DuVall S, Hayden CL, Knippenberg K, Morgan T, Pandya P, Han J, LaFleur (2014). Predicting Discontinuation of Pegylated Interferon as a Result of Lack of Efficacy in United States Veterans With Chronic Hepatitis C on Dual Therapy. The Annals of pharmacotherapy, 48(7), 826-836. (Read full article)
  5. Nelson RE, Hoop R, Korner E, DuVall S, Hayden CL, Knippenberg K, Morgan T, Pandya P, Jan J, LaFleur (2013). Predicting discontinuation of pegylated interferon due to lack of efficacy in United States veterans with chronic hepatitis C on dual therapy. The Annals of pharmacotherapy,
  6. LaFleur J, Nelson RE, Yao Y, Adler RA, Nebeker J (2012). Validated risk rule using computerized data to identify males at high risk for fracture. Osteoporosis international, 23(3), 1017-27. (Read full article)
  7. Nelson SD, Nelson RE, Cannon GW, Lawrence P, Battistone MJ, Grotzke M, Rosenblum Y, LaFleur (2014). Cost-effectiveness of training rural providers to identify and treat patients at risk for fragility fractures. Osteoporosis international, 25(12), 2701-7. (Read full article)
  8. LaFleur J, Nelson RE, Yao Y, Adler R, Nebeker J (2012). Validated risk rule using computerized data to identify males at high risk for fracture. Osteoporosis international, 23(3), 1017-27.
  9. Varier RU, Biltaji E, Jensen K, Smith KJ, Roberts MS, LaFleur J, Nelson R Cost-Effectiveness Analysis of Treatment Strategies for Initial Clostridium Difficile Infection. Infection control and hospital epidemiology,
  10. Bellows BK, LaFleur J, Kamauu AW, Ginter T, Forbush TB, Agbor S, Supina D, Hodgkins P, DuVall S (2014). Automated identification of patients with a diagnosis of binge eating disorder from narrative electronic health records. Journal of the American Medical Informatics Association, 21(e1), e163-8. (Read full article)
  11. LaFleur J, Nelson RE, Sauer BC, Nebeker J (2011). Overestimation of the effects of adherence on outcomes: a case study in healthy user bias and hypertension. Heart (British Cardiac Society), 97(22), 1862-9. (Read full article)
  12. Varier RU, Biltaji E, Jensen K, Smith KJ, Roberts MS, LaFleur J, Nelson R Cost-Effectiveness Analysis of Fecal Microbiota Transplantation versus Vancomycin for Recurrent Clostridium difficile Infection. Clinical microbiology and infection,
  13. Nelson RE, Nebeker JR, Hayden C, Reimer L, Kone K, LaFleur (2013). Comparing adherence to two different HIV antiretroviral regimens: an instrumental variable analysis. AIDS and behavior, 17(1), 160-7. (Read full article)
  14. LaFleur J, McAdam-Marx C, Alder SS, Sheng X, Asche CV, Nebeker J, Brixner DI, Silverman S (2011). Clinical risk factors for fracture among postmenopausal patients at risk for fracture: a historical cohort study using electronic medical record data. Journal of bone and mineral metabolism, 29(2), 193-200. (Read full article)
  15. Nelson RE, Butler J, LaFleur J, Kamauu A, Schuerch M, Fosket N, DuVall S Determining Multiple Sclerosis Subtype from Electronic Medical Records. Journal of managed care pharmacy,
  16. Nelson RE, McAdam-Marx C, Evans ML, Ward R, Campbell B, Brixner D, Lafleur (2011). Patent Extension Policy for Paediatric Indications: An Evaluation of the Impact within Three Drug Classes in a State Medicaid Programme. Applied health economics and health policy, 9(3), 171-81. (Read full article)
  17. Nelson SD, LaFleur J, Hunter E, Archer M, Steinvoort C, Maden C, Oderda G (2016). Identifying and Communicating Clinically Meaningful Drug-Drug Interactions. Journal of pharmacy practice, 29(2), 110-5. (Read full article)
  18. LaFleur J, Hoop R, Morgan T, DuVall SL, Pandya P, Korner E, Knippenberg K, Hayden C, Nelson R (2014). High rates of early treatment discontinuation in hepatitis C-infected US veterans. BMC research notes, 7, 266. (Read full article)
  19. Nelson RE, Battistone MJ, Ashworth WD, Barker AM, Grotzke M, Huhtala TA, Lafleur J, Tashjian RZ, Cannon G (2014). Cost effectiveness of training rural providers to perform joint injections. Arthritis care & research, 66(4), 559-66. (Read full article)
  20. Nelson RE, Xie Y, DuVall SL, Butler J, Kamauu A, Schuerch M, Foskett N, LaFleur Multiple Sclerosis and the Risk of Infection-Related Hospitalizations and Death Among US Veterans. International journal of MS care,
  21. Xie Y, LaFleur J, Kamauu A, Schuerch M, Foskett N, Nelson R Rates of Early Treatment for US Veterans with Multiple Sclerosis. SAGE open,

Abstract

  1. LaFleur J, Nelson RE, Hoop R, Morgan T, Pandya P, Nelson SD, Hamzeh (2011). Many United States veterans with chronic hepatitis-C discontinue pegylated interferon therapy for reasons other than non-response. Hepatology (Baltimore, Md.), 54(4), 799a.
  2. LaFleur J, Ghate SR, Sauer (2008). Updating the RxRisk-V: Creating a crosswalk between VA and FirstDataBank therapeutic categories. (Poster session presented at International Society for Pharmacoeconomics and Outcomes Research 13th Annual International Meeting. Toronto, Ontario, Canada. May 2008). Value in health, 11(3), A191.
  3. Ghate SR, LaFleur J, Sauer B, Charland (2008). A modified RxRisk-V comorbidity index predicts adherence with lipid lowering therapy. (Poster session presented at International Society for Pharmacoeconomics and Outcomes Research 13th Annual International Meeting. Toronto, Ontario, Canada. May 2008). Value in health, 11(3), A185.